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Abstract
Explicitly modeling underlying relationships between a survival endpoint and processes that 
generate longitudinal measured or reported outcomes potentially could improve the efficiency of 
clinical trials and provide greater insight into the various dimensions of the clinical effect of 
interventions included in the trials. Various strategies have been proposed for using longitudinal 
findings to elucidate intervention effects on clinical outcomes such as survival. The application of 
specifically Bayesian approaches for constructing models that address longitudinal and survival 
outcomes explicitly has been recently addressed in the literature. We review currently available 
methods for carrying out joint analyses, including issues of implementation and interpretation, 
identify software tools that can be used to carry out the necessary calculations, and review 
applications of the methodology.
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The objective of this article is a summary of currently available methods for joint modeling 
of survival data and longitudinal nonsurvival data with emphasis on Bayesian approaches, 
including evaluations of strengths and weaknesses of the various methods. We explore the 
practical implications of applying Bayesian approaches to the joint modeling of longitudinal 
and survival-type outcomes, with the aim of providing recommendations for how such 
models could or should be constructed, illustrating how they might be used, and elucidating 
the potential advantages they present and their limitations. We also evaluate software 
currently available for carrying out calculations needed for designs and data analyses, and 
identify needs for further software development.
1.1. General background
The joint modeling of survival with longitudinal data continues to be an active area of 
statistical methodological research. Much of the work has addressed improving efficiency 
and reducing bias in the survival component [1]. Accordingly, most of the inferential 
objectives have concerned characterization of survival estimates. Nonetheless, researchers as 
early as McArdle et al [2] have focused on the quantitative changes in the longitudinal 
trajectory component of these joint models. More recently, researchers have focused on the 
magnitude of the association between the survival and longitudinal data-generating 
processes to show person-level correspondence between these outcomes [3–5].
Joint modeling can benefit the analyses of both longitudinal and survival outcomes. The use 
of longitudinal mixed models to incorporate the effects of time-varying covariables in the 
evaluation of survival endpoints more accurately represents the quantitative influence of 
these factors on the survival estimates, compared with direct inclusion of the factor × time 
terms into the survival regression. Including survival information into the evaluation of the 
longitudinal observations directly incorporates the effect of an informative missing-data 
mechanism into the assessment of trends in these observations. Accounting for a clinical 
outcome as an informative censoring event is especially important when inferences about a 
longitudinal process are the key objective. Other approaches such as list-wise deletion to 
remove the uncensored cases or some form of averaging to retain them do not portray the 
true data-generating mechanism accurately.
The precision of the estimates of the parameters of the survival model, the longitudinal 
model, or both and, therefore, the accuracy of inferences about the underlying data-
generating mechanisms, may be increased by models that incorporate both kinds of 
outcome, especially if the outcomes are strongly associated. Increased sensitivity for 
detecting significant treatment effects can be particularly important when evaluating the 
longitudinal outcomes of RCTs. Practical and scientific considerations impose constraints 
that limit the trial size and result in designing studies to meet the criteria of primary study 
endpoints (e.g., overall or progression-free survival). Trial sizes are seldom large enough to 
provide adequate power for highly variable endpoints such as patient-reported outcomes 
(PROs), so that the increased sensitivity joint modeling can provide and offers the hope of 
detecting real treatment effects.
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Longitudinal values of objective measurements such as blood pressure and CD4 cell counts 
are familiar features of trials evaluating the effects of treatments or interventions on clinical 
outcomes such as disease progression or death. However, subjective measures also can be 
helpful for understanding the effects of the treatments or interventions. Indeed, corroborative 
support associating health outcomes as reflected in PROs can improve the interpretability of 
clinical measures. Moreover, information concerning how patients feel during and after 
treatment is a topic of growing interest, and addressing this information need will require 
more methodological development and more careful consideration when designing RCTs [1, 
6, 7].
There has been an increase in the desire to evaluate the patients’ perspectives by including 
specific questionnaires in clinical research programs [8–10]. Although the evaluation of 
subjective responses often is viewed as a soft science, the psychometrics used to develop, 
present, and analyze these data are at least as advanced as methods used for traditional 
clinical outcomes (e.g., overall survival). Nonetheless, results typically have been 
disappointing for various reasons, such as correct analyses not being based on appropriate 
study designs, inadequate data collection schedules, and nonmeaningful analyses driven by 
descriptive-only research hypotheses [1, 3, 4, 7].
The situation has been aggravated by the common practice of viewing quality of life (QOL) 
assessments or health outcomes information as supplementary information that is presented 
in separate trial protocols and analysis plans. This practice ignores the fact that these 
observations are like any other outcomes. Generally, symptom-based evaluations are more 
accepted by regulators (Food and Drug Administration PRO guidance) perhaps thereby 
elevating their status among other psychometrically-based constructs.
Experience from oncology trials suggests that there may be some practical constraints. The 
requirements for design and analysis of oncology clinical trials are well researched and 
documented [11, 12]. The prescribed endpoints are viewed as standard, particularly for 
developing oncology bio-pharmaceuticals, and essential for successful product registration 
and clinical use. However, as a practical matter, practitioners are trained and experienced in 
working with these standard outcomes, so that changing the methodology (e.g., from a Cox 
regression to a parametric non-PH model) generally would yield a different statistic but 
impart little or no additional useful clinical information upon which to base patient 
decisions. Hence, although joint modeling of survival and longitudinal data may improve 
oncology survival endpoint estimates, the pragmatism of regulators and practitioners might 
limit the widespread adoption of alternative approaches.
The Food and Drug Administration has published guidance on general principles of 
including PROs into RCTs with the goal of achieving label claims based on these 
assessments [13]. There is, however, evidence that operationalization and methodological 
gaps remain when seeking to meet standards for inclusion of PRO measures in RCTs [14]. 
The CONSORT-PRO extension offers a checklist of considerations for inclusion of PROs in 
RCTs, which includes specific mention of interpreting PRO data in relation to clinical 
outcomes, including survival data [15]. Additionally, general references are available to 
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inform the design and analysis of clinical studies that include PROs as study endpoints [16]. 
Nonetheless, these references do not provide detailed recommendations and rationale that 
are needed to overcome the traditional methodological challenges such as showing 
compelling evidence of the association across time between PROs and clinical endpoints as 
well as the need for comprehensive inclusion of PROs in the study design and analysis plans 
(e.g., including properly timed and sufficient collection of PRO data to provide internal 
validity and statistical power). There are no well-developed standards for the use of PROs in 
registration designs or in routine clinical practice for oncology or other therapeutic areas 
[13]. Progress has been made, so opportunities exist for outlining appropriate design and 
analysis principles for incorporating PRO outcomes into these studies. That said, it still is 
advisable to consult informative references before undertaking the design and analysis of 
clinical studies that include PROs as study endpoints.
Patient-reported outcome assessments should be developed routinely with the goal of 
correspondence to other well-known endpoints using traditional methods such as cross-
sectional correlation [17]. Demonstrating such correspondence at the patient level and 
longitudinally through the use of joint modeling would provide a more compelling rationale 
in support of the PRO validity. For example, when evaluating therapies for treating diabetes, 
PRO and longitudinal measurements should be linked to actual progression of diabetes, 
especially as manifested by recurrent events such as episodes of hypoglycemia.
Patient-level modeling of a recurring event, linked to a PRO trajectory, would inform the 
event antecedents thereby allowing characterization of factors associated with heterogeneity 
in treatment effect. Clinical trials often include many PROs in order to examine a wide 
range of patient outcomes. Under such a scenario, the correspondence between these 
different self-reported items and constructs would provide a much more data-informed 
picture upon which to evaluate the efficacy of an investigational compound.
1.3. Benefits of joint modeling [1, 18]
Joint models provide more efficient estimates of the treatment effects on the time to event 
and the longitudinal marker, and reduce bias in the estimates of the overall treatment effect 
[1, 5]. For example, if a particular drug reduces the hazard of a particular disease by 30%, 
then a joint model may lead to an estimated hazard ratio of 0.75, whereas a conventional 
model (e.g., a Cox model) that does not incorporate the longitudinal data into the analysis 
may yield a hazard ratio of 0.80. In this case, we say that the estimate based on the joint 
model is less biased than the Cox model estimate because 0.75 is closer to the true hazard 
ratio of 0.70. As a result, joint models are now increasingly used and often preferred over 
the Cox model alone because they yield more accurate and more precise estimates of the 
treatment effect. Greater efficiency implies higher power and smaller sample sizes in 
designing clinical trials. Thus incorporating the longitudinal data into the design of a study 
has the potential of yielding lower sample sizes with higher power compared with that of 
conventional designs based on time-to-event data alone.
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1.4. Challenges of joint modeling
Some of the practical challenges are those encountered by any technology seeking 
penetration into established practices and beliefs: fear of the new, unknown risk 
consequences of new methods, and so on. Overcoming these challenges will take time and 
demonstration of the benefits of joint modeling, which is one of the aims of this article.
The methodology does rely on assumptions about the random effects. However, recent work 
has shown that the robustness of the assumptions about random effects increases with the 
number of observations per subject [19, 20].
1.5. Other considerations/applications/extensions
The joint modeling of survival with semicontinuous data, that is, data characterized by a 
large portion of responses equal to a single value (e.g., zero or one on a bounded 0–1 scale), 
may be used to estimate a treatment-to-progress effect on oncology symptom data in 
otherwise healthy clinical trial enrollees reporting a strong floor effect corresponding to a 
general lack of symptoms. Under this scenario, right-skewed data with a mode at zero can be 
represented as a longitudinal two-part model consisting of a mixture of a binary and a 
continuous process, respectively, indicating the absence/presence of a symptom and the 
intensity of a symptom. The post-progression nonignorable absence of longitudinal data, by 
design collected until disease progression, can be incorporated through the joint modeling of 
progression-free survival with the longitudinal mixture [3, 4].
2. Joint models
Joint models generally consist of two parts: a model for event occurrence and a model for 
trajectory of longitudinal measurements that share some parameters. These two parts can be 
linked in various ways, which fall into three major categories: (i) naively using observed 
values of longitudinal variables as covariates in a Cox or parametric survival model; (ii) a 
two-stage approach in which a model first is fit to the longitudinal data, and then the fitted 
values of the longitudinal trajectory for each individual are used as covariates in the time-to-
event model; and (iii) using shared random effects in the models for the longitudinal and 
time-to-event likelihoods. Additional applications of joint models are described in what 
follows.
Joint models are not the same as survival models with time-varying covariates. The 
longitudinal data in these latter models just provide additional covariates to illuminate the 
survival process. The longitudinal observations in joint models are important in their own 
right, and the possibility of differential withdrawal (survival) raises the problem of 
differential bias and difficulty in understanding the true nature of the longitudinal process.
The following discussion addresses some specific issues associated with the definition and 
choice of various modeling approaches.
2.1. Longitudinal models
Longitudinal observations typically are described by a linear (usually) mixed model, (e.g., 
[21])
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β is a vector of fixed effects with corresponding time-varying design/covariate matrix. 
Xi(tij), bi is a vector of (usually normally distributed) random effects with corresponding 
time-varying design/covariate matrix Zi(tij). ui is a vector of time-invariant covariates (e.g., 
baseline measurements/assessments) contained in some larger set Ui(ui ℰ Ui).
Expression (1) can be generalized in various ways. The time dependence of the observations 
could be expressed by a simple polynomial regression or a more complex functional 
representation such as a spline regression could be used. The residual errors might not be 
independently distributed. The longitudinal measurements could themselves be vectors, so 
that survival or time to event might depend on a collection of correlated biomarkers or other 
longitudinal measurements, and not on just a single observable.
2.2. Survival models
‘Survival’ does not necessarily mean death. It could refer to a number of ‘terminating’ 
events such as progression of cancer, progression to full AIDS, progression of kidney failure 
to requiring dialysis, etc. In principle, although this is not addressed here, the events could 
be recurrent (see also [22–24]).
Survival models usually are employed in later-stage clinical trials as part of the evaluation of 
efficacy with respect to terminating endpoints. However, time-to-event models can also be 
used for safety endpoint modeling during early stages of development. Time to occurrence 
of toxicity is of particular interest in phase I oncology trials, for example, where late-onset 
toxicities become a serious concern for the development of targeted therapies [25]. Bayesian 
dose-finding methods based on time-to-toxic events currently are modeled using a single 
survival model [26, 27], but its joint use with a continuous PRO-endpoint such as pK 
(pharmacokinetics = measures of exchanges of administered doses among body 
compartments) or pD (pharmacodynamics = biological response measures such as blood 
pressure, EEG, and tumor volume) would allow a more accurate determination of the proper 
dose. In general, pK/pD model analyses proceed sequentially or simultaneously. The 
sequential approach first fits a model to the pK data and then fits a pD model to pD data 
using the expected value of pK predictions as covariates. With the simultaneous, or joint, 
approach (e.g., [28, 29]), the entire pK/pD model is fitted simultaneously to all of the data 
using shared parameters. The details, which are crucial and sometimes controversial, are 
outside the scope of this article. A number of software packages can be used to analyze 
pK/pD models, for example, WinBugs with the WBDiff package [30, 31], GNU MCSim 
[32], or NonMEM 7 [33]; considerations governing the choice of software are discussed in 
[34, 35].
2.2.1. Proportional hazards time-to-event model—The idea behind a joint model is 
to link the component processes together through some shared parameters. Let mi(t) denote 
the complete true unknown patient-specific longitudinal trajectory, and let Mi(t) = {mi(s); 0 
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≤ s ≤ t denote the corresponding true unknown longitudinal profile up to time t. We define 
the proportional hazards time-to-event submodel
(2)
where h0(t) is the baseline hazard function, vi ℰ Ui denotes a set of baseline time-
independent covariates, φ denotes the associated vector of log hazard ratios, and α denotes 
an interpretable association parameter. The quantity exp(α) is the hazard ratio for a one-unit 
increase in mi(t), at time t. Including the true unobserved trajectory function, mi(t), into the 
linear predictor of the proportional hazards model provides a way to link the component 
submodels to form the joint modeling framework, that is, to combine the functional 
representation (1) of the longitudinal observations with the survival submodel. Formulation 
(2) assumes that the association is based on the current value of the longitudinal response at 
time t. The survival function follows naturally
(3)
The time-dependent nature of the longitudinal process mi(t) means that the integral in (3) 
often will need to be calculated numerically, which complicates the estimation process.
In fact, the model does not have to depend only on the current value of a univariate 
longitudinal process [18, 36] and does not have to assume proportional hazards. Early work 
in the field of joint modeling chose the Cox model as the survival submodel of choice, 
which of course does not directly estimate the baseline hazard function [37–39]. This is both 
a strength and a weakness. Leaving the baseline hazard function unspecified avoids the need 
for assumptions about the underlying functional form. However, a parametric framework is 
more useful and convenient when the objective is to obtain absolute measures of risk, such 
as predictions of the outcomes for individual patients.
Moreover, a fully nonparametric survival model raises the problem of bias, because an 
unspecified baseline hazard leads to underestimation of the standard errors of parameter 
estimates [40]. Consequently, bootstrapping is required to obtain appropriate standard errors 
when incorporating the Cox model as the survival model of choice. The computationally 
intense numerical integration required to fit these models is an undesirable aspect of this 
particular joint modeling framework.
Using parametric survival distributions such as the exponential, Weibull, or Gompertz 
distributions avoids this issue, but assuming a standard survival distribution can restrict the 
range of baseline hazard functions that can be captured accurately. This has motivated 
alternative approaches, for example, using B-splines [36] or piecewise constant baseline 
hazard functions (e.g., [36, 41], but certainly other authors as well).
2.2.2. Proportional cumulative hazards time-to-event model—The flexible 
parametric survival model of Royston and Parmar provides an alternative to the commonly 
used parametric distributions [42]. This has recently been incorporated into the joint 
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modeling framework [21] by modeling on the log cumulative hazard scale instead of on the 
log hazard scale,
Flexibility is incorporated by using restricted cubic splines to model the baseline log 
cumulative hazard function.
2.2.3. Accelerated failure time models—The accelerated failure time framework can 
be used as the survival submodel, with covariates incorporated as described by Cox & Oates 
[43]
where S0(.) is the baseline survivor function, such as the Weibull distribution, log-normal 
distribution, log-logistic distribution, and generalized gamma distribution.
2.3. Alternative association structures
The parametrization of models relating the risk of the event at time t to the true unobserved 
longitudinal profile at that time often is called the current value parameterization. This is not 
the only way to relate longitudinal and time-to-event observations. Exploring alternative, 
clinically meaningful, ways of linking the two processes expands the usefulness of the joint 
modeling framework.
2.3.1. Interaction effects—The joint model association structure just described assumes 
the same association between the true longitudinal value and the risk of event for all 
patients. Sometimes it may be more realistic to allow for different values of association for 
different patient subgroups. This can be achieved by forming interactions between the 
baseline covariates and the true unobserved longitudinal trajectory function, as follows:
The quantities vi1 and vi2(vi1, vi2 ℰ Ui) are time-invariant baseline covariates; vi1 is the same 
as in (2) and (3). The new covariates vi2 are interaction covariates that multiply the true 
longitudinal profiles (as above), so that the association parameters α can reflect different 
associations for different covariate patterns. The association structure reduces to the 
standard current value parameterization when vi2 = 1.
2.3.2. Time-dependent slope—The association structures described earlier incorporate 
the current value of the true longitudinal response. But they could as well incorporate the 
rate of change of the true longitudinal response, especially when the direction and strength 
of trend of a biomarker are as important as its level at any point in time. That is, (2) could be 
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Ye et al incorporated this association structure into a two-stage regression calibration joint 
model [44]. Wolbers et al described the added benefit of including the rate of change of 
CD4 trajectories within a joint model framework to model the risk of progression to AIDS 
or death in HIV-positive patients [45].
2.3.3. Random effects parameterization—Yet another time-independent association 
structure includes only the random effects in the linear predictor of the survival submodel,
(5)
This formulation includes both the population level mean of the random effect, plus the 
subject specific deviation. This model can be simplified by including only the subject-
specific deviation,
(6)
The association parameters in (5) and (6) have different interpretations. Suppose, for 
example, that the longitudinal trajectories are described by a random intercept and random 
slope model,
The hazard ratio at time t = 0 that reflects association between patient-specific values of the 
true longitudinal outcome at t = 0 can be evaluated using
where exp(α1) is the hazard ratio for a one-unit increase in the baseline value of the 
longitudinal outcome, that is, the intercept. If only the subject-specific deviations are 
included (model (6)), then the hazard becomes
Gould et al. Page 9













which assumes that the association is based only on the subject-specific deviation from the 
population mean intercept. The function h0(t) does not include covariate effects that may be 
relevant at baseline, so the second factor adjusts the baseline hazard function to 
accommodate these effects.
The associations assuming time independence must be interpreted cautiously. For example, 
linking the random coefficients of the spline terms when the random effects of a longitudinal 
trajectory function are described by complex functions such as fractional polynomials or 
splines leads to uninterpretable association parameters. From a computational perspective, 
however, the time-independent association structures are particularly useful because they 
lead to directly computable closed functional forms for the cumulative hazard function.
2.4. Bayesian methods for joint modeling of longitudinal and survival data
The methods reviewed thus far for joint modeling have been based on a frequentist 
approach. The parameters were obtained by maximizing the likelihood or partial likelihood 
[46]. However, it often may be advantageous to apply a Bayesian approach. In the Bayesian 
paradigm, asymptotic approximations are not necessary, model assessment is more 
straightforward, computational implementation is typically much easier, and historical data 
can be incorporated easily into the inference procedure. This section describes three 
Bayesian approaches [47–49], all of which use the Wulfsohn and Tsiatis [39] general model 
building approach.
All three Bayesian approaches use a proportional hazards model for the survival component 
of the model. Where they differ is in the modeling of the longitudinal component. Ibrahim, 
Chen, and Sinha [48] used a random effects model with a multivariate outcome. Faucett and 
Thomas [47] used a univariate random effects model. Wang and Taylor [49] also used a 
random effects model but included an integrated Ornstein-Uhlenbeck process that added 
more flexibility to the trajectory curve, but greatly increased the number of parameters in the 
model and the computational complexity. Note: an integrated Ornstein-Uhlenbeck process is 
the only nontrivial random process that is stationary, Gaussian, and Markovian, and allows 
linear transformations of the space and time variables. It is used commonly to model the 
error distribution in semiparametric regression models, e.g., [50]. All of these approaches 
used Gibbs sampling to obtain realizations from the joint posterior distribution of the 
parameters.
Faucett and Thomas [47] took a Bayesian approach to solving the same random effects and 
proportional hazards models as Wulfsohn and Tsiatis [39]. They used non-informative priors 
on all the parameters in order to achieve similar results to maximum likelihood approaches. 
Wang and Taylor [49]) introduced another Bayesian method for jointly modeling 
longitudinal and survival data.
Joint models can become very complex very quickly, especially when multiple events are 
considered and the longitudinal observations are multivariate. This is especially true when 
the models include subject-specific random effects that must be removed or accounted for. 
Frequentist methods attempt to do this by integrating with respect to the distributions of 
these random effects, an approach that can become computationally unstable, if not 
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altogether infeasible, when there are many such effects or when the models are very 
complex. Bayesian approaches provide a practicable way to address complex models that 
incorporate multivariate survival, multivariate longitudinal observations (e.g., multiple 
symptoms—pain, breathing difficulties, cardiovascular symptoms—see [36] for an 
example). Moreover, the application of Bayesian methods do not require assuming 
normality for the distributions of the random quantities.
2.5. Additional considerations
Even though survival depends on ‘true’ longitudinal model Mi(tij), only the observed 
longitudinal values Yi(tij) are known, so that the censoring implied by the survival 
component may be informative. If the hazard function depends on the entire longitudinal 
trajectory, there may be bias because only snapshots in time and not the whole trajectory are 
observed [18]. This potential problem could be addressed by an appropriate longitudinal 
model relating outcome to time, for example, via spline regression.
The joint modeling framework can be used to assess the effect of a longitudinal trajectory of 
observable values on the probability of occurrence of some event. Some care is needed in 
the interpretation because the analysis of the survival component incorporates time-
dependent covariates that necessarily are measured with error even though models such as 
those described earlier are functions of the unknown true longitudinal trajectories.
The framework also can be used to assess the potential effect of the occurrence of an event 
on the distribution of observed outcomes, which raises some issues. The event occurrence 
may cause a subject to withdraw from observation so that the opportunity for subsequent 
longitudinal measurements is lost. This poses a potential informative censoring issue 
because the probability of the event may depend on the actual or true values of the 
observations not made. Standard time-to-event methods such as proportional hazard models 
cannot be used when this happens.
Sweeting and Thompson compared three approaches with joint modeling via simulation and 
via application to the prediction of abdominal aortic aneuryism growth and rupture [51]. The 
three approaches were (1) naively using observed values of longitudinal variables as 
covariates in a Cox or parametric survival model, (2) using shared random effects in the 
models for the longitudinal and time-to-event likelihoods, and (3) using a two-stage 
approach in which a model was first fit to the longitudinal data and then the fitted values of 
the longitudinal trajectory for each individual were used as covariates in the time-to-event 
model. Software for the analyses of these models is readily available, including the jm and 
joineR packages available in R. The supplementary material for their paper provides code 
for carrying out Bayesian analyses using WinBUGS or OpenBUGS. Sweeting and 
Thompson found that naively using the observed data as covariates (approach 1) led to 
severe underestimation, that using fitted values as covariates (approach 3) led to bias and 
poor coverage properties, but that the shared effect method (approach 2), although not 
perfect, performed acceptably well.
Gould et al. Page 11














3.1. JM joint modeling R package [52]
The JM package is designed to fit a variety of joint models for normal longitudinal 
responses and time-to-event data using maximum likelihood. The package is extensively 
documented, with worked examples. The main arguments of the key function in the package 
(jointModel()) are a linear mixed effects object as returned by the lme() function from the 
nlme package and a survival object returned by the coxph() or survreg() functions in the 
survival package. A number of relative risk and accelerated failure time survival model 
options are available, including Weibull, piecewise proportional hazards, Cox proportional 
hazards, and proportional hazards with a spline-approximated baseline risk function. A wiki 
page, http://rwiki.sciviews.org/doku.php?id=packages:cran:jm provides information on 
continuing developments plus detailed analyses of real data sets. No special expertise 
appears to be required to use the package other than a knowledge of what is being 
calculated.
3.2. joineR R package [53]
The joineR package implements methods for analyzing data from longitudinal studies based 
on an extended Wulfsohn and Tsiatis model [39] in which the response from each subject 
consists of a time sequence of repeated measurements and a possibly censored time-to-event 
outcome. The modeling framework for the repeated measurements is a linear model with 
random effects and/or correlated error structure. The model for the time-to-event outcome is 
a Cox proportional hazards model with log-Gaussian frailty. Stochastic dependence is 
captured by allowing the Gaussian random effects of the linear model to be correlated with 
the frailty term of the Cox proportional hazards model. If λi(t) denotes the hazard for subject 
i and Yij, the jth repeated measurement on subject i, the model specifies latent vectors Ui 
and Vi that follow zero-mean multivariate normal distributions, realized independently for 
different subjects. Given Ui and Vi, the repeated measurements submodel is
and the hazard submodel is
where xij, aij, wij, and bij are vectors of possibly time-varying explanatory variables and the 
Zij are mutually independent, Zij ~ N(0, τ2). Although this model formulation is flexible in 
principle, the computational cost of evaluating the likelihood restricts routine 
implementation of the model to low-dimensional Ui and Vi.
The package is well documented, and an accompanying report clearly describes its use with 
a number of examples. No special level of expertise appears to be necessary to use the 
package other than a knowledge of what is being calculated.
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3.3. Bayesian joint models in WinBUGS (or OpenBUGS) and SAS®
Guo and Carlin describe the application of the Markov chain Monte Carlo (MCMC) 
approach as implemented in WinBUGS [54] to a joint analysis of longitudinal data and 
survival times [55]. The code for carrying out the analysis is available from the website 
http://www.biostat.umn.edu/~brad/software.html. In addition to the WinBUGS code, the 
website also provides code for carrying out similar calculations using the NLMIXED 
procedure in SAS® written by Oliver Schabenberger. The joint model approach uses shared 
latent random effects that appear in both the longitudinal and survival submodels. The 
longitudinal submodels are of the form
where yij denotes the measurement on subject i at the jth measurement occasion for that 
subject, tij denotes the corresponding time point,  denotes the possibly time-dependent 
fixed effects, and W1i(tij) = U1i + U2itij is the sum of random intercept and slope effects 
corresponding to subject i. The survival submodels express the logarithm of the hazard at 
time t as
where h(t) is a baseline hazard that depends on the model used (exponential/Weibull or Cox 
proportional hazards), ξi(t) denotes possibly time-dependent fixed effects, and W2i(t) denotes 
the random effect contribution, generally expressed as
where the shared U1i and U2i are as for the longitudinal model and U3i is an optional random 
frailty term that is independent of U1i and U2i. The models were applied jointly and 
separately to data from a trial comparing two antiretroviral drugs. The parameter estimates 
from the separate and joint models were similar, but the joint model provided a more 
accurate and clinically realistic estimate of the median survival time as a function of 
baseline characteristics. Simulations of the performance of the method in three scenarios 
indicated satisfactory performance in all cases.
3.4. JMBayes R package [56]
This package fits shared parameter models for the joint modeling of normal longitudinal 
responses and event times under a Bayesian approach using JAGS, WinBUGS, or 
OpenBUGS. The package has a single model-fitting function that accepts as main arguments 
a linear mixed effects object fit returned by function lme() of package nlme and a Cox 
model object fit returned by function coxph() of package survival. The method allows for 
joint models with relative risk survival submodels with Weibull or B-spline approximated 
baseline hazard functions. The association structure between the longitudinal and survival 
process can be specified in various ways. One can optionally use the classic joint model 
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formulation of Wulfsohn and Tsiatis (1997), or define possibly time-dependent, term so as 
to include terms, such as the time-dependent slope (i.e., the derivative of the subject-specific 
linear predictor of the linear mixed model), and the time-dependent cumulative effect (i.e., 
the integral of the subject-specific linear predictor of the linear mixed model), or combine 
these two possibilities, or include only the random effects of the linear mixed model in the 
linear predictor of the survival submodel. The package also provides functionality for 
computing dynamic predictions for the longitudinal and time-to-event outcomes.
3.5. Bayesian/frequentist fit package (JMFit) [57]
The JMfit package is a joint modeling frequentist SAS software package that fits several 
types of shared parameter joint models. The longitudinal model is allowed to be a linear 
mixed model, and the survival model is allowed to be a piecewise constant hazards model 
with random effects. Six types of trajectories can be used for the longitudinal model. The 
software produces maximum likelihood estimators of the parameters, standard errors and the 
AIC and BIC goodness of fit statistics. This is the first joint modeling software package that 
allows for simultaneously fitting and evaluating joint models. It includes decompositions of 
the AIC and BIC statistics that allow the user to assess the contribution of the longitudinal 
data to the survival component of the model.
3.6. stjm Stata package [58]
The stjm package implements joint modeling of a normal longitudinal response and a time-
to-event using maximum likelihood, with an emphasis on parametric time-to-event models. 
The package is documented with examples in the help file and an associated Stata journal 
paper. The data setup is consistent with standard survival analysis with time-varying 
covariates, requiring only a single call to the main function, stjm, to fit a joint model. The 
longitudinal outcome can be modeled flexibly using fixed/random polynomials or splines. 
The survival probabilities can be modeled using exponential, Weibull, Gompertz 
proportional hazards models, the Royston–Parmar flexible parametric model, Weibull-
Weibull and Weibull-exponential mixture models, and spline-approximated baseline (log) 
hazard function.
Associations between the survival and longitudinal components can be expressed by the 
current longitudinal measurement value at a time point, the slope of the longitudinal 
trajectory at that time point, and random effects with or without a fixed mean; all of these 
can be considered separately or in combination. Estimation of the parameters can be 
accomplished using nonadaptive or fully adaptive Gauss–Hermite quadrature. No special 
level of expertise is required other than a knowledge of what is being calculated.
4. Examples of applications
4.1. HIV/AIDS
Immunologic and virologic markers are measured repeatedly over time on each patient in 
clinical trials of therapies for diseases associated with human immunodeficiency virus 
(HIV). The intervals between data collection times vary in length, and missing data are quite 
common. The markers are prone to measurement error and high within patient variability 
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because of biological fluctuations [59–61]. Modeling these covariates over time is preferable 
to using the raw data [46, 62–65]. In addition, models provide estimates for time points 
where data are not available. Many HIV clinical trials focus on the opportunistic infections 
(OI) associated with HIV disease where the survival endpoint is the time to development of 
the OI [66–73]. In these trials, immunologic and virologic markers might be utilized as time-
varying predictor variables.
The most common measure used to assess immunological health is the CD4+ lymphocyte 
count or CD4 count for short. Higher CD4 counts indicate a stronger immune system that is 
more prepared to resist infection. Lower CD4 counts indicate a higher risk of an OI. Viral 
load is a measure of the amount of virus in the blood plasma. A lower viral load is preferable 
and may indicate successful treatment of the disease. A patient’s success on treatment is 
often evaluated by these two markers. When a patient begins a successful treatment regimen, 
the viral load may drop drastically and fall below a detectable level. The CD4 count may 
take longer to respond or may not respond at all. As viral load decreases, we may expect the 
CD4 count to increase as the immune system has time to recover. However, CD4 count is 
slower to respond than viral load. Because of this complex relationship between the 
immunologic and virologic markers, we may want a multivariate model for longitudinal 
covariates. These trajectories are generally difficult to model parametrically; therefore, we 
may want to allow for more flexibility in the curve by considering semiparametric or 
nonparametric models [50, 74].
4.2. Cancer vaccine trials
In cancer vaccine (immunotherapy) trials, vaccinations are given to patients to raise the 
patients’ antibody levels against the tumor cells. In these studies, the time-to-event end point 
is often the time to disease progression or time to death. A successful vaccine activates the 
patient’s immune system against future tumor growth so that a patient’s antibody production 
increases to help eradicate tumors. Therefore, measurements of these antibodies may be 
associated with the time-to-event and may help the clinician to evaluate the vaccination 
before the event occurs. Ibrahim, Chen, and Sinha [48] presented a Bayesian joint model in 
a cancer vaccine study for patients with malignant melanoma. They performed a survival 
analysis adjusting for longitudinal immunological measures. The primary measures of 
antibody response were the IgG and IgM antibody titers. The levels of these markers were 
conjectured to be associated with the clinical outcome and were therefore monitored during 
follow-up. These markers are prone to measurement error so that the raw data should not be 
used in a survival analysis. A method that jointly models the longitudinal marker as well as 
the survival outcome is necessary.
4.3. Health related quality of life studies
The collection of QOL data in clinical trials has become increasingly common, particular 
when the survival benefit of a treatment is anticipated to be small or moderate. In fact, one 
might argue that QOL is at times an even more important factor in treatment decisions for a 
patient than any modest survival benefit. Besides the trade-offs between survival benefits 
and therapeutic adverse effects on QOL, QOL may be predictive of survival. A survival 
model that incorporated both treatment and QOL information is necessary. Often a QOL 
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survey instrument is administered to patients at a number of prespecified time points during 
follow-up. Complete QOL data for patients at all of the specified collection times are 
frequently unavailable, and measurement errors may occur for any single QOL assessment 
because of the imperfect reliability of the instrument. A joint modeling of longitudinal and 
survival data is not only able to evaluate the therapeutic impacts on both QOL and survival 
outcome but also able to investigate the prognostic impact of patients’ QOL. The 
measurement errors as well as the missingness of QOL assessments can also be managed by 
the longitudinal submodel of a joint model. Because different facets of QOL, such as 
appetite, mood, and physical well-being, are often assessed with a survey instrument, a 
multivariate model for the longitudinal QOL is necessary to model different dependence 
structures among observations.
4.4. Renal graft failure
Rizopoulos and Ghosh [36] developed a semiparametric model for time to event data with 
multivariate longitudinal observations for each subject. Spline models were used to express 
the true trajectories of the longitudinal observations, in order to capture with some fidelity 
the highly nonlinear pattern of variation demonstrated by the longitudinal observations. That 
is, given the values of the random effects corresponding to individuals, a known link 
function of the expected value of a sequence of measurements could be expressed in terms 
of a true, unknown, function that the authors approximated using splines. The approximation 
had two parts: a time-independent part and a time-dependent part, both with fixed and 
random effects. The relative hazard for the event time model was assumed to depend on the 
true longitudinal trajectories and on various random effects corresponding to latent effects 
shared with the longitudinal observations. A key point that the authors made is the need for 
careful consideration of how the models should be parametrized, and they discussed in some 
detail alternative ways to express the models. They also described some tools for evaluating 
the effect of different choices of parameterizations. The plethora of random and latent 
effects in the models makes a Bayesian approach attractive and practical.
The approach was applied to data on 407 patients with chronic kidney disease undergoing 
primary renal transplantation; the longitudinal data consisted of three markers related to 
graft function and survival. Joint modeling of the multiple outcomes was needed to evaluate 
association of each with graft failure risk after adjusting for others. Application of 
alternative models showed that correction for the effects of the other markers affected the 
strength of the association between a marker and the risk of graft failure. The spline function 
representation economically captured the main features of the subject-specific longitudinal 
trajectories, which were markedly nonlinear. The authors also observed that ‘…observed 
data may not contain enough information to distinguish between the different 
paramterizations without prior knowledge.’
4.5. Scleroderma lung study
Huang et al [75] described the application of joint modeling with competing risks to the 
analysis of data from a comparison of the effects of oral cyclophosphamide on the 
progression of scleroderma-related interstitial lung disease as expressed by changes from 
baseline in percent forced vital capacity (FVC) or the occurrence of (i) disease-related 
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withdrawal or (ii) treatment failure or death. The joint model used included a linear mixed 
effects submodel for the longitudinal outcomes (values of FVC over time), a proportional 
hazards competing risks survival submodel with cause-specific hazards including frailty, and 
a regression model for the covariance matrix of the multivariate latent random effects. This 
latter model incorporates separate regression models for the diagonal and off-diagonal 
elements, and allows the covariance matrices to vary among subjects, which is a new 
feature. Bayesian methods (MCMC) were used to avoid high-dimensional integration to 
remove latent effects.
Patients were assigned at random to a year of treatment with cyclophosphamide or placebo, 
and followed for a subsequent year. In addition to treatment and time, the covariates 
included baseline FVC and baseline lung fibrosis, plus their interactions with treatment. A 
linear spline fixed effects model was used with a change point at month 18. Two models for 
the covariance structure of the random effects were used, one that assumed homogeneity 
across subjects and one that modeled heterogeneity of the covariance matrices. It turned out 
that there was insufficient evidence from these data to reject the assumption of covariance 
matrix homogeneity. Simulation studies demonstrated that the heterogeneity model leads to 
almost unbiased parameter estimates, while the homogeneity model can lead to large biases 
in some parameter estimates.
5. Discussion and recommendations
The objective of this report was to illustrate how joint modeling methods actually can 
provide value for drug development. It was not our aim to provide another review of joint 
modeling methods, because there are many very good reviews, but rather to provide 
motivation to sponsors to use the methods and a jumping-off point for statisticians wanting 
to apply them. The key message is that joint modeling methods can be used, perhaps even 
routinely, to link survival-type outcomes with longitudinal measurements to get better 
insights into both.
One of the considerations that make joint modeling challenging is the complexity of the 
calculations that result from the need to integrate with respect to the distributions of the 
random effects even with fairly simple situations that involve a single longitudinal outcome 
and a single survival event. This in particular is why the more recent developments in the 
field have employed Bayesian methods to remove the need for explicit multivariate 
integration. Bayesian methods also provide a way to incorporate multiple longitudinal 
outcomes and multiple competing survival events. They also provide a path for addressing 
even more complex models that could include recurrent as well as absorbing effects.
We sought to accomplish our goal by describing specific areas of application that could 
benefit from joint modeling, by outlining in some detail how the calculations proceed, by 
identifying software that can be used to carry out the calculations (perhaps the most crucial 
part), and by identifying published applications that actually used joint modeling methods. 
The technical and practicability obstacles to using joint modeling for many applications in 
medical product development have pretty well been overcome. It is not clear, however, that 
sufficient attention has been given to the interpretability and clinical interpretation of the 
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results of analyses based on joint models, primarily because most discussions of joint model 
methods have been in the technical statistical literature. The challenge now is to encourage 
statisticians and managers in the pharmaceutical and medical product industries to embrace 
rather than resist the new, to their benefit and to the benefit of the public at large.
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